FDx Advisors Inc. lowered its position in Novo Nordisk A/S (NYSE:NVO) by 22.5% in the third quarter, HoldingsChannel.com reports. The firm owned 6,003 shares of the company’s stock after selling 1,745 shares during the quarter. FDx Advisors Inc.’s holdings in Novo Nordisk A/S were worth $283,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Green Square Capital LLC lifted its position in Novo Nordisk A/S by 12.2% in the second quarter. Green Square Capital LLC now owns 11,177 shares of the company’s stock valued at $515,000 after purchasing an additional 1,216 shares during the period. Polen Capital Management LLC lifted its position in Novo Nordisk A/S by 5.0% in the third quarter. Polen Capital Management LLC now owns 25,750 shares of the company’s stock valued at $1,214,000 after purchasing an additional 1,231 shares during the period. Somerville Kurt F lifted its position in Novo Nordisk A/S by 6.5% in the third quarter. Somerville Kurt F now owns 20,299 shares of the company’s stock valued at $957,000 after purchasing an additional 1,235 shares during the period. Willingdon Wealth Management lifted its position in Novo Nordisk A/S by 2.4% in the third quarter. Willingdon Wealth Management now owns 57,951 shares of the company’s stock valued at $2,732,000 after purchasing an additional 1,334 shares during the period. Finally, Boston Common Asset Management LLC lifted its position in Novo Nordisk A/S by 0.9% in the second quarter. Boston Common Asset Management LLC now owns 149,793 shares of the company’s stock valued at $6,908,000 after purchasing an additional 1,391 shares during the period. Hedge funds and other institutional investors own 6.84% of the company’s stock.

Shares of Novo Nordisk A/S stock opened at $45.38 on Friday. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $58.37. The stock has a market capitalization of $111.62 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 2.41 and a beta of 0.75.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Thursday, November 1st. The company reported $0.58 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.58. Novo Nordisk A/S had a net margin of 34.94% and a return on equity of 81.50%. The company had revenue of $4.31 billion during the quarter, compared to analysts’ expectations of $4.11 billion. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 2.45 EPS for the current year.

A number of brokerages have issued reports on NVO. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. UBS Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Monday, November 26th. Kepler Capital Markets reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, November 29th. Pareto Securities raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, November 26th. Finally, ValuEngine raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, October 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $64.00.

TRADEMARK VIOLATION WARNING: “Novo Nordisk A/S (NVO) Position Reduced by FDx Advisors Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/novo-nordisk-a-s-nvo-position-reduced-by-fdx-advisors-inc/2669613.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Featured Story: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.